Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 15/20 | 0.40 |
| ▸ | AKT2 | P31751 | 6/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1904810 | 0.99 | AURKA (0.45) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1903666 | 0.90 | AURKA (0.53) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1901584 | 0.89 | AURKA (0.48) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1901101 | 0.88 | CHEK1 (0.43) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1901833 | 0.88 | CHEK1 (0.43) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1903977 | 0.88 | AURKA (0.48) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL12095491 | 0.87 | AURKA (0.44) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1904186 | 0.86 | AURKA (0.43) | AURKACHEK1MAP2K1AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1904455 | 0.86 | AURKA (0.43) | AURKACHEK1MAP2K1AKT1AKT2 | |
| SCHEMBL1900137 | 0.84 | AURKA (0.43) | AURKACHEK1MAP2K1AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | claimed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | claimed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AURKA 527/4885CHEK1 168/4885MAP2K1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.